Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Brice

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocolP Brice, D Simon, R Bouabdallah, et al.
The American Journal of Surgical Pathology|July 1, 1996
Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") studyD Cazals-Hatem, E Lepage, P Brice, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 1999
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'AdulteB Coiffier, E M Neidhardt-Bérard, H Tilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 TrialP Solal-Céligny, E Lepage, N Brousse, et al.
The British Journal of Dermatology|January 5, 2021
Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndromeJ Calvani, A de Masson, C de Margerie-Mellon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
The British Journal of Dermatology|May 15, 2020
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomasA Dangien, C Ram-Wolff, P Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocolP Brice, D Simon, R Bouabdallah, et al.
The American Journal of Surgical Pathology|July 1, 1996
Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") studyD Cazals-Hatem, E Lepage, P Brice, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 1999
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'AdulteB Coiffier, E M Neidhardt-Bérard, H Tilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 TrialP Solal-Céligny, E Lepage, N Brousse, et al.
The British Journal of Dermatology|January 5, 2021
Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndromeJ Calvani, A de Masson, C de Margerie-Mellon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
The British Journal of Dermatology|May 15, 2020
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomasA Dangien, C Ram-Wolff, P Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Pageof 15